Kurt Kara: We bought this pharmaceutical company for the portfolio

In its December 2023 update, Kurt Kara and the team behind their Value Stocks fund provide an update and developments in the portfolio portfolio. Here they mention, among other things, that the ECB and the Bank of England both rejected the end of the fight against inflation. According to Kara, this put a damper on the market, which was otherwise positively affected by announcements from the Fed to lower interest rates in 2024.

Here they also unveil a new position that they have added to the portfolio: the American pharmaceutical manufacturer Johnson & Johnson. In relation to the portfolio, they write:

The American company Johnson & Johnson, which among other things manufactures products in the healthcare field, was added to the portfolio. The company has consistently demonstrated the ability to deliver high returns on invested capital. The stock was bought at 15 times estimated earnings. We divested the position in Intel to finance the acquisition of Johnson & Johnson. Intel has delivered a good performance in 2023, but in our opinion, Johnson & Johnson was a more attractive company on quality and valuation at the time of acquisition.

Share the news

Disclaimer of liability

The above has been prepared by Børsgade ApS for information purposes and cannot be regarded as a solicitation or recommendation to buy or sell any security. Nor can the information etc. be regarded as recommendations or advice of a legal, accounting or tax nature. Børsgade cannot be held liable for losses caused by customers’/users’ actions – or lack thereof – based on the information in the above. We have made every effort to ensure that the information in the above is complete and accurate, but cannot guarantee this and accept no liability for errors or omissions.

Readers are advised that investing may involve a risk of loss that cannot be determined in advance, and that past performance and price development cannot be used as a reliable indicator of future performance and price development. For further information please contact info@borsgade.dk

You might also find this interesting:

Michael Mauboussin: Everything is a DCF Model

In this article, Michael Mauboussin argues that whenever investors value a stake in a cash-generating asset, they are essentially using a discounted cash flow (DCF) model, whether explicitly or implicitly.

Aswath Damodaran: Nvidia And The Power Of Expectations

In this article, Aswath Damodaran delves into the complex interplay between corporate earnings reports, market expectations, and stock price movements, using Nvidia’s recent earnings announcement as a case study.

Guy Spier: A Masterclass On Building Wealth, Wisdom & Success

In this interview, Guy Spier covers a wide range of topics, blending practical investing advice with broader life lessons and philosophical insights. Guy emphasizes the importance of long-term thinking, personal growth, and maintaining a balanced perspective on success and happiness.